Is AbCellera Biologics Inc. (NASDAQ:ABCL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating AbCellera Biologics Inc. at current levels.
Antibody discovery factory pivoting to owning the drugs it finds, with two Phase 1/2 readouts that could re-rate the whole thesis.
Where ABCL is headed
By the back half of 2027, AbCellera looks like a different company than the COVID-antibody one-hit-wonder Wall Street wrote off in 2022. The pivot is from royalty-fed discovery engine to vertically integrated clinical-stage biotech, with two wholly-owned programs (ABCL635 for vasomotor symptoms, ABCL575 for atopic dermatitis) carrying data the market can actually price. Vasomotor symptoms is a market Astellas already validated when Veozah cleared half a billion in run-rate sales despite a black-box liver warning. A clean non-hormonal molecule walks into that gap. ABCL575 is a half-life extended OX40L antibody, going after the same biology Sanofi paid $20B to acquire Kymera-adjacent assets in. AbCellera owns 100% of both.
Read the full Compass Direction on ABCL
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $8.12).
See the full ABCL analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is AbCellera Biologics Inc. (NASDAQ:ABCL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating AbCellera Biologics Inc. at current levels. Antibody discovery factory pivoting to owning the drugs it finds, with two Phase 1/2 readouts that could re-rate the whole thesis.
What is ABCL's Compass Score?
AbCellera Biologics Inc. scores 87/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ABCL?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ABCL page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.